Publication: Cyclooxygenase-2 expression in gastroenteropancreatic neuroendocrine tumors
| dc.contributor.authors | Ince, Ali Tuzun; Ovunc, Oya; Celikel, Cigdem Ataizi; Goksel, Suha; Tosun, Serhan; Peker, Oender | |
| dc.date.accessioned | 2022-03-12T17:33:02Z | |
| dc.date.accessioned | 2026-01-11T05:57:06Z | |
| dc.date.available | 2022-03-12T17:33:02Z | |
| dc.date.issued | 2007 | |
| dc.description.abstract | Background/Aims: The aim of this multicenter study was to investigate cyclooxygenase-2 protein expression in gastroenteropancreatic neuroendocrine tumors and to examine the relationship to various clinicopathological parameters. Methodology: Thirty-seven gastroenteropancreatic neuroendocrine tumor specimens were analyzed immunohistochemically. Correlations between expression and some parameters such as age, sex, tumor size, location, presence of multiple neuroendocrine tumor, lymphatic/vascular/muscularis propria invasion and lymph node metastases were evaluated. Results were interpreted as significant if p < 0.05. Results: Mean age of patients (15 men/22 women) was 52 +/- 17. Tumor size varied between 0.1 and 12cm. (mean; 3.17 +/- 3.29cm). Expression was detected in 75% of cases and in 92% of gastric neuroendocrine tumors. Expression in mixed endocrine and non-endocrine carcinomas was found to be significantly higher than in well-differentiated 'neuroendocrine tumors and carcinomas (p=0.016). A relationship was observed between overexpression and lymphatic and vascular invasion (p=0.029). However, no significant correlation was found between expression and sex, tumor location, size; muscularis propria invasion and lymph node metastasis. Conclusions: Cyclooxygenase-2 expression may play a role in the evolution of gastroenteropancreatic neuroendocrine tumors. However, further studies are necessary to determine the importance of this role, prognostic relevance and whether cyclooxygenase isoenzyme can be a target for treatment in these tumors. | |
| dc.identifier.doi | doiWOS:000247568100033 | |
| dc.identifier.issn | 0172-6390 | |
| dc.identifier.pubmed | 17629053 | |
| dc.identifier.uri | https://hdl.handle.net/11424/228757 | |
| dc.identifier.wos | WOS:000247568100033 | |
| dc.language.iso | eng | |
| dc.publisher | H G E UPDATE MEDICAL PUBLISHING S A | |
| dc.relation.ispartof | HEPATO-GASTROENTEROLOGY | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.subject | cyclooxygenase-2 | |
| dc.subject | non-steroidal | |
| dc.subject | anti-inflammatory drugs | |
| dc.subject | neuroendocrine tumors | |
| dc.subject | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | |
| dc.subject | HUMAN GASTRIC-CANCER | |
| dc.subject | CELL-CYCLE ARREST | |
| dc.subject | COLORECTAL-CANCER | |
| dc.subject | CLINICOPATHOLOGICAL FEATURES | |
| dc.subject | COX-2 INHIBITION | |
| dc.subject | BREAST-CANCER | |
| dc.subject | COLON-CANCER | |
| dc.subject | CARCINOMA | |
| dc.subject | GROWTH | |
| dc.title | Cyclooxygenase-2 expression in gastroenteropancreatic neuroendocrine tumors | |
| dc.type | article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 1129 | |
| oaire.citation.issue | 76 | |
| oaire.citation.startPage | 1125 | |
| oaire.citation.title | HEPATO-GASTROENTEROLOGY | |
| oaire.citation.volume | 54 |
